Review: vaccines against human papillomavirus prevent cervical cancer precursors in young women

摘要

QUESTIONDo vaccines against human papillomavirus (HPV) prevent cervical cancer precursors in young women?METHODSData sources: Medline and EMBASE/Excerpta Medica (to May 2007); Medline in process (to June 2007); Cochrane Library and Cochrane Central Register of Controlled Trials (Issue 1, 2007); conference proceedings (2004-7); clinical trial registers; Google Scholar; public health announcements; reference lists; and vaccine manufacturers. Study selection and assessment: randomised controlled trials (RCTs) that compared a vaccine against > =1 oncogenic type of HPV with placebo or no HPV vaccine for prophylaxis of oncogenic HPV-related infection and disease in women. 9 reports of 6 RCTs (n = 40 323; mean age 20 y, range 15-26 y) met the selection criteria. 1 RCT (n = 2392) evaluated a monovalent HPV 16 vaccine, 2 RCTs (n = 19 757) evaluated a bivalent HPV 16/18 vaccine, and 3 RCTs (n = 18 174) evaluated a quadrivalent HPV 6/11/16/18 vaccine. Quality assessment of individual trials was based on the Jadad scale and allocation concealment; all 6 RCTs were of high methodological quality.